Skip to content
Screener

Krystal Biotech, Inc. KRYS Q4 2025 Annual earnings

Reported February 17, 2026 · Before market open

Revenue$107.1MBeat by $1.8M
EPS$1.70Beat by $0.08
Revenue estimate$105.3M
EPS estimate$1.62

Next report

Nov 2, 2026 (in a month)
Revenue estimate$129.1M
EPS estimate$1.91

Financials

Q4 2025

Income statement

See full
Revenue$107.1M+17.5%
Operating income$44.3M+7.0%
Net income$51.4M+13.0%
EPS (diluted)$1.70+11.1%

Balance sheet

See full
Cash & equivalents$496.3M+43.9%
Total debt$9.3M+28.6%
Total equity$1.2B+28.9%
Total assets$1.3B+26.3%

Cash flow

See full
Operating cash flow$77.5M+46.7%
CapEx$2.1M+167%
Free cash flow$75.4M+44.8%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$7.15B+58.7%
Enterprise value$6.66B+59.8%
P/E34.9×-15.6×
P/S18.4×+2.9×

Profitability

See full
Operating margin41.4%+18.8pp
Net margin52.6%+21.9pp
FCF margin48.5%+5.7pp

Returns & leverage

See full
Return on equity18.9%+8.6pp
Debt / equity0×0.0×
Current ratio10×+2.7×

FAQ

When did Krystal Biotech, Inc. report Q4 2025 earnings?
Krystal Biotech, Inc. (KRYS) reported Q4 2025 earnings on February 17, 2026 before market open.
What were Krystal Biotech, Inc.'s Q4 2025 revenue and EPS?
Krystal Biotech, Inc. reported revenue of $107.1M and eps of $1.70 for Q4 2025.
Did Krystal Biotech, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $105.3M by $1.8M. EPS beat the consensus estimate of $1.62 by $0.08.
How did Krystal Biotech, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 17.5% from $91.1M a year earlier and eps grew 11.8% from $1.52.
Where can I find Krystal Biotech, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001711279-26-000018) and the 10-K periodic report (0001711279-26-000016) directly on SEC EDGAR. The filing index links above go to sec.gov.